TG Therapeutics: Ramifications Of Briumvi Approval

People who succeed in the stock market also accept periodic losses, setbacks, and unexpected occurrences - Peter Lynch

Author's Note:?This is an abbreviated version of an article originally published in advance inside Integrated BioSci Investing?for our members.

In biotech investing, an FDA approval is a major fundamental improvement for a small biotech company. After all, it is a validation of the sound science and medicine of the drug. Moreover, it represents the fruits of competent management. Notwithstanding, approval is only half of the battle won, i.e., the easier half. The more difficult challenge is commercialization, which will determine the ultimate fate of the company.

That being said, TG Therapeutics, Inc. (NASDAQ:TGTX) recently erased all market doubts about the ability of its lead medicine (ublituximab) to clear the?FDA hurdle. Approved and to be marketed under the brand Briumvi, the drug offers a differentiated solution to patients afflicted by the dreaded condition (multiple sclerosis). In this research, I'll elucidate the ramifications of this approval. More importantly, I'll share with you my expectation of this stock.

YOU CAN EITHER READ THE 1)?FREE ARTICLE?ON SEEKING ALPHA OR 2)?IN-DEPTH ANALYSIS?INSIDE INTEGRATED BIOSCI INVESTING.